Navigation Links
1 in 5 heart-attack deaths could be prevented with new drug
Date:6/13/2011

Robert Storey, Professor of Cardiology at the University of Sheffield's Department of Cardiovascular Science, presented findings today that confirm one in five deaths in the year following a heart attack could be prevented if a new drug, ticagrelor, was used instead of the standard treatment, clopidogrel.

Professor Storey's latest findings were presented at the British Cardiovascular Society annual scientific conference in Manchester today (Monday 13 June 2011).

Professor Storey has led UK investigations of ticagrelor and was a member of the international committee that conducted the PLATO study, a trial of over 18 thousand patients in over 40 countries around the world. The results of the PLATO study were first presented at the European Society of Cardiology congress in 2009, showing that ticagrelor was more effective for heart attack patients than clopidogrel in reducing death and recurrent heart attack.

A new analysis of the PLATO study presented this year at the American College of Cardiology showed that ticagrelor is just as effective at reducing deaths in patients over the age of 75 as in younger patients. Professor Storey commented: "Our new findings really highlight the universal applicability of the treatment."

Ticagrelor was made available in the UK in December 2010 but has not yet been adopted across most of the UK due to cost concerns. Clopidogrel has a very low cost as it is available in generic forms, whereas ticagrelor is more expensive at around 55 per month. However, the excess drug cost of ticagrelor is offset to some extent by its greater effectiveness which reduces the need for heart operations.

Professor Storey commented: "Many people are dying avoidably in the year after having a heart attack due to delays introducing this new treatment. These new findings provide yet further evidence in support of making the drug available to patients in the UK. We're pleased that the Scottish Medicine Consortium recently approved ticagrelor, on the basis that the initial expense of the drug is offset to a significant extent by the resultant savings, such as reduced need for procedures. In England, a verdict from NICE is awaited but final guidance is not expected until October."

One of the problems with clopidogrel is that about a quarter of people in the UK have a genetic variant that reduces the effect of the drug and are at greater risk. A sub-study of the PLATO trial was published in the Lancet confirming that patients treated with clopidogrel, who have such a genetic variant, have a slightly higher risk in the first month following heart attack but ticagrelor is not affected by this variant and is still more effective than clopidogrel, regardless of a patient's genetic make-up.

A common side-effect of ticagrelor is a sense of breathlessness which is usually mild and well-tolerated. Professor Storey presented data at the European Society of Cardiology meeting in 2010 showing that even patients who develop this side-effect still seem to have the reduced mortality risk compared to clopidogrel-treated patients. Another analysis led by Professor Storey showed that patients who develop breathlessness on ticagrelor do not show any problems on heart or lung tests, providing reassurance about the benign nature of ticagrelor-related breathlessness.

Professor Storey has been involved with the development of ticagrelor and related drugs for the past 15 years. 90 patients from Sheffield, with acute coronary syndrome, were recruited for the PLATO trial, which involved over 18,000 cardiac patients worldwide. One of the questions that is currently unanswered is whether continuing ticagrelor beyond 1 year after a heart attack will lead to continued benefit. This question will be addressed by the PEGASUS study which has recently started in the UK and many other countries, recruiting patients who are within 2 years of completing their one year course of treatment following a heart attack.

Professor Storey commented: "PEGASUS is an exciting study that will recruit 21,000 patients around the world, looking at whether ticagrelor added to aspirin is more effective at preventing problems related to clotting in the arteries than the standard anti-clotting treatment of aspirin only. Another study (ATLANTIC) planned to start in the next few months will also assess whether it is more effective to treat patients with full-blown heart attack with ticagrelor in the ambulance rather than wait until patients arrive at the hospital to have the blocked artery opened by balloon angioplasty."


'/>"/>

Contact: Amy Stone
a.f.stone@sheffield.ac.uk
44-114-222-1046
University of Sheffield
Source:Eurekalert

Related medicine news :

1. Diversion of ambulances associated with increased risk of death for heart-attack patients
2. Dairy consumption does not elevate heart-attack risk, study suggests
3. Preventing avoidable opioid-related deaths top priority for pain medicine field
4. Deaths and major morbidity from asbestos-related diseases in Asia likely to surge in next 20 years
5. Unintentional child injuries, deaths can be prevented, public health researchers say
6. Evidence-Based Heart Attack Care Reduces Deaths: Study
7. Narcotic pain relief drug overdose deaths a national epidemic
8. Deaths from drug overdose decline 35 percent after the opening of supervised injection site
9. Motorcycle Deaths Drop for Second Straight Year: Report
10. Overdose deaths down 35 percent after opening of Vancouvers supervised injection site: UBC-BC-CfE study
11. Unemployment Plays Role in Early Deaths, Research Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... CA (PRWEB) , ... February 06, 2016 , ... With ... and easily add warm color grades to their footage. A LUT is a Lookup ... pixel's color to the corresponding color indicated by the table. By manipulating each pixel, ...
(Date:2/5/2016)... ... February 05, 2016 , ... VeloReality President and ... generation LYNX VR Indoor Trainer with multi-rider capability to an enthusiastic audience at ... only reduce the weight of the unit, they also enhance the rider's experience ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... to announce the addition of micro-needling services in their Napa Valley office. The ... founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of ...
(Date:2/5/2016)... San Rafael, CA (PRWEB) , ... February 05, 2016 , ... ... partnership with ChildLight Yoga Studio in Dover, NH to direct high-performance kids yoga training. ... on New Hampshire’s seacoast, just one hour from Boston. , ChildLight Yoga Studio founder ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of the nation’s ... weekend’s Big Game. Take the stress out of your party preparation – follow these ... at every stage of the game. , “The key to hosting a successful game-day ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016 France , Germany ... UK, and Israel ). It includes a 10-year epidemiology ... GD, segmented by age and sex in these markets. GD epidemiology report ... is in-depth, high quality, transparent and market-driven, providing expert analysis of disease ... Germany , Italy , Spain ...
(Date:2/4/2016)... IRVINE, Calif. , Feb. 4, 2016  Edwards ... in patient-focused innovations for structural heart disease and critical ... an accelerated share repurchase (ASR) agreement with Morgan Stanley ... common stock.  This repurchase is part of the Company,s ... of the Company,s common stock.  ...
(Date:2/4/2016)... YORK , Feb. 4, 2016   Bernstein Liebhard ... been filed in the United States District Court for the ... a class (the "Class") consisting of all persons or entities ... the "Company") (NASDAQ: INSY ) from March 3, 2015 ... Insys and certain of its officers with violations of the ...
Breaking Medicine Technology: